Altria Group, Inc.

NYSE•MO

CEO: Mr. William F. Gifford Jr.

Sector: Consumer Defensive

Industry: Tobacco

Listing Date: 1985-07-01

Altria Group, Inc., through its subsidiaries, manufactures and sells smokeable and oral tobacco products in the United States. The company offers cigarettes primarily under the Marlboro brand; large cigars and pipe tobacco under the Black & Mild brand; moist smokeless tobacco and snus products under the Copenhagen, Skoal, Red Seal, and Husky brands; oral nicotine pouches under the on! brand; and e-vapor products under the NJOY ACE brand. It sells its products to distributors, as well as large retail organizations, such as chain stores. The company was founded in 1822 and is headquartered in Richmond, Virginia.

Contact Information

6601 West Broad Street, Richmond, VA, 23230, United States

804-274-2200

www.altria.com

Market Cap

$112.71B

P/E (TTM)

16.2

19.4

Dividend Yield

6.2%

52W High

$70.51

52W Low

$52.82

52W Range

81%

Rank13Top 2.2%

6.8

F-Score

Modified Piotroski Analysis

Based on 10-year fundamentals

Strong • 6.8 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2016-2025

Financial Dashboard

Q4 2025 Data

Revenue

$5.85B+14.49%

4-Quarter Trend

EPS

$0.66-63.33%

4-Quarter Trend

FCF

$3.18B-3.46%

4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Adjusted Earnings Growth Adjusted Net Earnings grew 2.4% to $9.15B USD; Adjusted Diluted EPS increased 4.4% to $5.42 USD.

Cigarette Volume Decline Total cigarette shipments fell 10.0% to 61.8B units in 2025, driven by down-trading pressures.

Major E-Vapor Impairments Recorded $2.13B in asset impairment charges, including $1.16B goodwill impairment for e-vapor unit.

Share Repurchase Activity Repurchased $1.0B common stock during Q4 2025 under the January 2025 program authorization.

Risk Factors

Illicit E-Vapor Competition Illicit flavored disposable e-vapor products continue to drive cigarette volume decline and challenge growth.

E-Vapor Asset Devaluation E-vapor reporting unit goodwill impaired by $1.16B due to protracted enforcement against illicit flavored products.

Tobacco Litigation Uncertainty Ongoing tobacco and health litigation remains subject to uncertainty, potentially resulting in material adverse effects.

Premium Brand Down-trading Macroeconomic pressures caused consumers to reduce consumption and purchase lower-priced discount brands.

Outlook

2028 EPS Growth Target Targeting mid-single digit adjusted diluted EPS CAGR by 2028 from a $4.87 base in 2022.

Optimize & Accelerate Savings Initiative expects to deliver cumulative savings of at least $600M by the end of fiscal year 2029.

Progressive Dividend Goal Maintain progressive dividend goal targeting mid-single digits dividend per share growth annually through 2028.

Smoke-Free Portfolio Focus Remain committed to building FDA-authorized smoke-free product portfolio beyond current nicotine categories.

Peer Comparison

Revenue (TTM)

$123.01B

-7.0%

TGT

$105.64B

-1.4%

BUD

$89.38B

+0.0%

Gross Margin (Latest Quarter)

100.0%

+0.0pp

BTI

83.4%

+1.1pp

62.1%

-8.5pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
UL	$145.15B	28.6	26.0%	42.0%
BUD	$142.87B	14.1	12.3%	33.4%
BTI	$129.18B	12.4	16.3%	32.1%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

9.0%

Steady Growth

4Q Net Income CAGR

1.2%

Profitability Slowly Improving

Cash Flow Stability

100%

Strong Cash Flow

Deep Research

Next earnings:Apr 27, 2026

EPS:-

Revenue:-

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data